Compare AXR & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AXR | FATE |
|---|---|---|
| Founded | 1961 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.0M | 125.6M |
| IPO Year | 2010 | 2013 |
| Metric | AXR | FATE |
|---|---|---|
| Price | $22.94 | $2.31 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $30.00 | $4.10 |
| AVG Volume (30 Days) | 7.4K | ★ 1.2M |
| Earning Date | 03-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.88 |
| EPS | ★ 1.91 | N/A |
| Revenue | ★ $12,831,000.00 | $6,646,000.00 |
| Revenue This Year | $10.12 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.02 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.61 | $0.94 |
| 52 Week High | $29.01 | $3.23 |
| Indicator | AXR | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 46.47 | 41.80 |
| Support Level | $21.68 | $2.27 |
| Resistance Level | $23.52 | $2.88 |
| Average True Range (ATR) | 0.53 | 0.13 |
| MACD | 0.07 | -0.01 |
| Stochastic Oscillator | 39.01 | 28.21 |
Amrep Corp through its subsidiaries is engaged in the Real estate business. Its activities include land sales and lease activities, which involve obtaining approvals and selling both developed and undeveloped lots to homebuilders, commercial users, and others, as well as investments in commercial and investment properties. The Company accounts for land sales, home sales, and other revenues. Its operating segments include Land development and Homebuilding. The firm generates a majority of its revenue from the Land development segment. Geographically, all the activities are carried out throughout the United States.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.